Clinical Trial Update: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study of isatuximab in combination with cemiplimab in relapsed/refractory multiple myeloma, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Isatuximab (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-14